Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam

作者：Castaldo Nadia; Givone Filippo; Peghin Maddalena; Righi Elda; Sartor Assunta; Bassetti Matteo^*

来源：Journal of Global Antimicrobial Resistance, 2017, 9: 100-102.

DOI：10.1016/j.jgar.2017.02.012

• Ceftolozane/tazobactam
• Pseudomonas aeruginosa
• Multidrug resistance
• MDR
• Skin and soft-tissue infection

Ceftolozane/tazobactam (C/T) is a novel beta-lactam/beta-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum beta-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T.

• 出版日期2017-6